Recombinant constructs of
Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.
1. A nucleic acid encoding a protein comprising at least a first and a second polypeptide, wherein the first polypeptide comprises OspC from Borrelia burgdorferi sensu lato and wherein the second polypeptide comprises OspA from Borrelia burgdorferi sensu lato, such that the first polypeptide is linked to the N-terminus of the second polypeptide.
2. A nucleic acid encoding a protein comprising at least a first and a second polypeptide, wherein the first polypeptide comprises OspC from Borrelia burgdorferi sensu lato from amino acid residue 19 to amino acid residue 211, wherein amino acid numbering is according to the OspC polypeptide numbering of SEQ ID NO: 30, and wherein the second polypeptide comprises OspA from Borrelia burgdorferi sensu lato selected from the group consisting of:
(a) a Borrelia burgdorferi sensu lato OspA polypeptide from amino acid residue 18 to amino acid residue 273,
(b) a Borrelia burgdorferi sensu lato OspA polypeptide from amino acid residue 132 to amino acid residue 216,
(c) a Borrelia burgdorferi sensu lato polypeptide comprising at least two separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 18 to amino acid residue 216 from a first strain of Borrelia burgdorferi sensu lato, and wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 217 to amino acid residue 273 from a second strain of Borrelia burgdorferi sensu lato,
(d) a Borrelia burgdorferi sensu lato polypeptide comprising at least two separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 132 to amino acid residue 216 from a first strain of borrelia burgdorferi sensu lato, and wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 217 to amino acid residue 273 from a second strain of Borrelia burgdorferi sensu lato, and
(e) a Borrelia burgdorferi sensu lato polypeptide comprising at least four separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 30 to amino acid residue 150, wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 151 to amino acid residue 179, wherein the third OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 181 to amino acid residue 216 and, wherein the fourth OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 216 to amino acid residue 273, wherein at least two of the OspA polypeptide fragments are from different strains of Borrelia burgdorferi sensu lato, wherein amino acid numbering of OspA polypeptide is according to the OspA polypeptide numbering of SEQ ID NO: 7.
3. A nucleic acid encoding a protein comprising at least a first and a second polypeptide, wherein the first polypeptide comprises OspC from Borrelia burgdorferi sensu lato from amino acid residue 19 to amino acid residue 204, wherein amino acid numbering is according to the OspC polypeptide numbering of SEQ ID NO: 30, and wherein the second polypeptide comprises OspA from Borrelia burgdorferi sensu lato selected from the group consisting of:
(a) a Borrelia burgdorferi sensu lato OspA polypeptide from amino acid residue 18 to amino acid residue 273,
(b) a Borrelia burgdorferi sensu lato OspA polypeptide from amino acid residue 132 to amino acid residue 216,
(c) a Borrelia burgdorferi sensu lato polypeptide comprising at least two separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 18 to amino acid residue 216 from a first strain of Borrelia burgdorferi sensu lato, and wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 217 to amino acid residue 273 from a second strain of Borrelia Borrelia sensu lato,
(d) a Borrelia burgdorferi sensu lato polypeptide comprising at least two separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 132 to amino acid residue 216 from a first strain of Borrelia burgdorferi sensu lato, and wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 217 to amino acid residue 273 from a second strain of Borrelia burgdorferi sensu lato, and
(e) a Borrelia burgdorferi sensu lato polypeptide comprising at least four separate OspA polypeptide fragments, wherein the first OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 30 to amino acid residue 150, wherein the second OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 151 to amino acid residue 179, wherein the third OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 181 to amino acid residue 216 and, wherein the fourth OspA polypeptide fragment comprises an OspA polypeptide from amino acid residue 216 to amino acid residue 273, wherein at least two of the OspA polypeptide fragments are from different strains of Borrelia burgdorferi sensu lato, wherein amino acid numbering of OspA polypeptide is according to the OspA polypeptide numbering of SEQ ID NO: 7.
4. A nucleic acid of any one of claims 1 , 2 , or 3 , wherein the first polypeptide is from a first strain of Borrelia burgdorferi sensu lato and the second polypeptide is from a second strain of Borrelia burgdorferi sensu lato.
5. A nucleic acid of any one of claims 1 , 2 , or 3 , wherein the first polypeptide is from a first genospecies of Borrelia burgdorferi sensu lato and the second polypeptide is from a second genospecies of Borrelia burgdorferi sensu lato.
6. A nucleic acid selected from the group consisting of: SEQ ID NOs: 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.
7. An expression vector comprising an isolated DNA having a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.
8. An expression vector comprising an isolated DNA encoding a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.
9. A host cell comprising a recombinant nucleic acid having a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.
10. A host cell comprising a recombinant nucleic acid encoding a protein having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.
11. A physiological composition to vaccinate against and treat Borrelia infection in animals or humans, the composition comprising;
a) a nucleic acid that encodes a chimeric protein comprising at least a first and a second polypeptide, wherein the first polypeptide comprises OspC from Borrelia burgdorferi sensu lato and wherein the second polypeptide comprises OspA from Borrelia burgdorferi sensu lato, such that the first polypeptide is linked to the N-terminus of the second polypeptide; and
b) a physiologically-acceptable carrier or vehicle.
12. The composition of claim 11 , wherein the nucleic acid is selected from the group consisting of: SEQ ID NOs: 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.